R33 AI116184 (Kean)
NIH/NIAID
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation
The goal of this project is to explore the mechanisms by which haplo-identical bone marrow transplantation can cure HIV infection using a non-human primate model.
Specific Aims: The specific aims of this project are (1) to create a Non-human Primate Model of Haploidentical HCT for HIV Eradication and (2) to determine whether haploidentical HCT using HIV-resistant stem cells expressing the mC46 resistance factor can eradicate the viral reservoir from SHIV-c infected RMs.
Role: Principal Investigator
NIH/NIAID
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation
The goal of this project is to explore the mechanisms by which haplo-identical bone marrow transplantation can cure HIV infection using a non-human primate model.
Specific Aims: The specific aims of this project are (1) to create a Non-human Primate Model of Haploidentical HCT for HIV Eradication and (2) to determine whether haploidentical HCT using HIV-resistant stem cells expressing the mC46 resistance factor can eradicate the viral reservoir from SHIV-c infected RMs.
Role: Principal Investigator
R33 AI116184 (Kean)
NIH/NIAID
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques
This project seeks to find new insights into the biology of organ-specific T cell pathophysiology, new therapeutic options for GVHD treatment, and new approaches to tolerogenic GVHD prevention.
Specific Aims: The specific aims of this project involve (1) evidence-based GVHD Prevention, (2) tissue-specific GVHD diagnostics, and (3) evidence-based GVHD treatment
Role: Principal Investigator
NIH/NIAID
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques
This project seeks to find new insights into the biology of organ-specific T cell pathophysiology, new therapeutic options for GVHD treatment, and new approaches to tolerogenic GVHD prevention.
Specific Aims: The specific aims of this project involve (1) evidence-based GVHD Prevention, (2) tissue-specific GVHD diagnostics, and (3) evidence-based GVHD treatment
Role: Principal Investigator
U19 AI051731 (Larson)
Emory University/NIAID
Project 2: Transplant Tolerance in Non-Human Primates
The goal of this project is to use mixed-chimerism- and Treg-based approaches to induce specific immunologic tolerance during bone marrow and renal transplantation in a rhesus macaque MHC-defined transplant model.
Specific Aims: The specific aims of this project are (1) to engineer an optimally suppressive regulatory T cell product, able to provide allograft-specific immune tolerance after renal transplantation; (2) to induce immune tolerance to a renal allograft through the induction of stable, multilineage mixed-hematopoietic chimerism and preservation of protective immunity in the setting of T cell costimulation blockade.
Role: Principal Investigator
Emory University/NIAID
Project 2: Transplant Tolerance in Non-Human Primates
The goal of this project is to use mixed-chimerism- and Treg-based approaches to induce specific immunologic tolerance during bone marrow and renal transplantation in a rhesus macaque MHC-defined transplant model.
Specific Aims: The specific aims of this project are (1) to engineer an optimally suppressive regulatory T cell product, able to provide allograft-specific immune tolerance after renal transplantation; (2) to induce immune tolerance to a renal allograft through the induction of stable, multilineage mixed-hematopoietic chimerism and preservation of protective immunity in the setting of T cell costimulation blockade.
Role: Principal Investigator
Core B: Transplant Tolerance in Non-Human Primates
The goal of this core is to support all projects being performed as part of the Transplant Tolerance in Non-Human Primates U19 in the following areas: (1) MHC immunogenetic analysis; (2) Determining the impact of transplantation on anti-viral protective immunity; (3) Transplant-specific histopathology; and (4) Multiparameter flow-cytometric immune analysis.
Specific Aims: The specific aims of this project are (1) to engineer an optimally suppressive regulatory T cell product, able to provide allograft-specific immune tolerance after renal transplantation; (2) to induce immune tolerance to a renal allograft through the induction of stable, multilineage mixed-hematopoietic chimerism and preservation of protective immunity in the setting of T cell costimulation blockade.
Role: Principal Investigator
The goal of this core is to support all projects being performed as part of the Transplant Tolerance in Non-Human Primates U19 in the following areas: (1) MHC immunogenetic analysis; (2) Determining the impact of transplantation on anti-viral protective immunity; (3) Transplant-specific histopathology; and (4) Multiparameter flow-cytometric immune analysis.
Specific Aims: The specific aims of this project are (1) to engineer an optimally suppressive regulatory T cell product, able to provide allograft-specific immune tolerance after renal transplantation; (2) to induce immune tolerance to a renal allograft through the induction of stable, multilineage mixed-hematopoietic chimerism and preservation of protective immunity in the setting of T cell costimulation blockade.
Role: Principal Investigator
U19 HL129902 (Cannon)
USC/FHCRC
Next Generation HSC Gene Therapy for HIV Control and Eradication Project 1:
Defining HIV Sanctuary Sites During Autologous and Allogeneic Transplantation The goal of this project is to investigate the ability of hematopoietic stem cell transplantation with HIV-resistant cells to eradicate the viral reservoirs that persist during cART and cure HIV, having the potential to contribute to the healthy lives of HIV-infected patients, by producing a definitive cure of their disease.
Specific Aims: The specific aims of this project are (1) to create an anatomic, cellular and temporal map of transplant-resistant sanctuary sites after auto-HCT with gene-modified, SHIVresistant hematopoietic stem cells (HSCs); (2) to determine the ability of allo-HCT, with and without SHIV-resistant cells, to clear the viral reservoir.
Role: Principal Investigator
USC/FHCRC
Next Generation HSC Gene Therapy for HIV Control and Eradication Project 1:
Defining HIV Sanctuary Sites During Autologous and Allogeneic Transplantation The goal of this project is to investigate the ability of hematopoietic stem cell transplantation with HIV-resistant cells to eradicate the viral reservoirs that persist during cART and cure HIV, having the potential to contribute to the healthy lives of HIV-infected patients, by producing a definitive cure of their disease.
Specific Aims: The specific aims of this project are (1) to create an anatomic, cellular and temporal map of transplant-resistant sanctuary sites after auto-HCT with gene-modified, SHIVresistant hematopoietic stem cells (HSCs); (2) to determine the ability of allo-HCT, with and without SHIV-resistant cells, to clear the viral reservoir.
Role: Principal Investigator
FP01024468 (Kean/Stenger)
Thrasher Research Fund/Emory
Acute GVHD Suppression Using Co-Stimulation Blockade to Expand Non-Malignant Transplant – ASCENT
Specific Aims: Dr. Leslie Kean will be responsible for overseeing the clinical trial laboratory correlatives being completed in her laboratory. This will include flow cytometry and viral assay of 26 patients x 10 timepoints.
Role: Co-Principal Investigator
Thrasher Research Fund/Emory
Acute GVHD Suppression Using Co-Stimulation Blockade to Expand Non-Malignant Transplant – ASCENT
Specific Aims: Dr. Leslie Kean will be responsible for overseeing the clinical trial laboratory correlatives being completed in her laboratory. This will include flow cytometry and viral assay of 26 patients x 10 timepoints.
Role: Co-Principal Investigator
Biopharma collaborations
The Kean lab has ongoing collaborations with the following biopharma companies:
- Bristol Myers Squibb
- Regeneron
- Magenta
- Bluebird Bio
